Email Updates

You are here

Home

20 NOVEMBER 2020 VOLUME 22 ISSUE 45

Media Coverage

  • Injectable PrEP Tops List As the Preferred Choice for Adolescent Girls in Cape Town

    Adolescent girls prefer long-acting injections and the vaginal ring over daily pills as their product of choice for both contraception and pre-exposure prophylaxis (PrEP) for HIV prevention finds a study from Cape Town, South Africa. The study looked at contraceptive choices of adolescent girls (ages 15 to 19) to establish what type of pre-exposure prophylaxis (PrEP) product they might prefer.

    November 20, 2020
    PrEP
    Avert

  • Opinion: Why Exciting Results From Vaccine Research Are Just the Beginning of Efforts to End COVID-19

    The news last week and again this week that at least two highly effective vaccines may be on the horizon is a welcome respite from the devastating impact of COVID-19 on global health. In under a year, SARS-CoV-2 has already caused more than 56 million infections and 1.3 million deaths.

    November 19, 2020
    General
    Devex

  • Government to Launch HIV Self-Testing Vending Machines

    The government plans to launch HIV self-testing electronic vending machines (EVMs) next month. According to Catherine Ngugi, the head, division of the National AIDS and STIs Control Programme (NASCOP), the launch will be held during World AIDS Day in Kajiado County.

    November 19, 2020
    General
    The Standard

  • HIV Death Rates Fell by Half, CDC Says

    Deaths related to HIV in the United States fell significantly from 2010 through 2018, regardless of sex, age, race or region, the Centers for Disease Control and Prevention reported on Thursday. The death rate declined over all by about half, a welcome sign in the fight against the virus, experts said. But the data also highlighted some troubling trends: Gains among women, Black people and those of multiple races were much smaller. And the rate of death was about twice as high in Southern states as in the Northeast.

    November 19, 2020
    Treatment
    New York Times

  • Long-Lasting Anti-AIDS Meds Eliminate 'Psychic Toll' Of Daily Pill

    Steven used to take a pill every morning to control his HIV. Then he heard about a study for a ground-breaking treatment where he wouldn't have to take any pills at all. "I get an injection in each butt cheek once a month," says Steven, an attorney based in Pittsburgh, Pa., who tested positive in 2015.

    November 19, 2020
    PrEP, Treatment
    NPR

  • HIV Death Rate in SA Men Much Higher Than in Women

    While men account for only a third of South Africa’s roughly 200,000 new HIV infections in the year ending mid-2019, they account for more than half of the approximately 74,000 HIV-related deaths in the same period.

    November 18, 2020
    Treatment
    Spotlight

  • TB Policies Aren’t Working. Here’s Why

    Tuberculosis has long suffered from limited tools for testing and treatment, but a new report finds that it also faces policy disparities between what is recommended globally and what is rolled out in countries.

    November 18, 2020
    General
    Devex

  • 'Uptake Is Only the First Step' for Effective HIV PrEP Protection

    Same-day HIV pre-exposure prophylaxis (PrEP) prescriptions and insurance navigation services led 70 percent of people at a Detroit sexually transmitted infection clinic to ask for a PrEP prescription. But only 40 percent of those same people came back for a follow-up appointment, and 5 acquired HIV during the review period.

    November 17, 2020
    PrEP
    Medscape

  • Millions of People Are on Treatment for HIV: Why Are So Many Still Dying?

    Twenty years ago treatment for HIV was a rare luxury in South Africa. Exorbitant costs and President Thabo Mbeki’s government’s fierce opposition to providing antiretroviral treatment (ART) kept it out of the public sector.

    November 17, 2020
    Treatment
    The Conversation

  • Six Injections a Year Could Stop New HIV Infections

    Six shots a year of an antiretroviral (ARV) drug can protect women from contracting HIV, new research shows. Activists say although the jab won’t be available immediately, countries need to start doing the planning—and the math—to introduce the bimonthly injection now.

    November 16, 2020
    PrEP
    Mail & Guardian

  • Merck Launches Major Trial of Monthly Islatravir PrEP Pill for Women

    Partnering with the Bill & Melinda Gates Foundation, pharmaceutical giant Merck will launch a major, late-stage trial of a monthly pill form of the antiretroviral islatravir as pre-exposure prophylaxis (PrEP) against HIV among women and adolescent girls at risk for the virus.

    November 16, 2020
    PrEP
    POZ

Published Research

Announcements